Compare AMETEK, Inc. (AME) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Cardinal Health Inc — how do they compare? AMETEK, Inc. trades at $258.03 (market cap $58.76B), while Cardinal Health Inc trades at $238.83 (market cap $55.88B). The key difference: AMETEK, Inc. and Cardinal Health Inc are close in size by market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| AME | CAH | |
|---|---|---|
Market Cap | $58.76B | $55.88B |
Sector | Industrials | Health |
52-Week High | $256.30 | $240.26 |
52-Week Low | $179.28 | $146.04 |
Enterprise Value | $60.30B | $59.91B |
Dividend Yield | 0.53% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.
Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
